Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
| Brand name | QUINAPRIL |
| Generic name | QUINAPRIL |
| Active ingredient(s) | QUINAPRIL HYDROCHLORIDE |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, by: Lupin Limited, Goa 403 722 India |
| NDC | 68180-558-09 |
| Full product label | Quinapril Tablets USP, 20 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, by: Lupin Limited, Goa 403 722 India, NDC# 68180-558-09 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed by major distribution chains nationwide. |
| Quantity | 23,736 |
| Recall initiated | 2022-12-07 |
| Report date | 2022-12-28 |
| Recall completed | 2024-08-01 |
| Recall number | D-0089-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗